Evidence map›Paper›PMID 34944097›Full record

ArticleCells2021

Unravelling the Impact of the Genetic Variant rs1042058 within the TPL2 Risk Gene Locus on Molecular and Clinical Disease Course Patients with Inflammatory Bowel Disease.

Yasser Morsy, Nathalie Brillant, Yannick Franc, Michael Scharl, Marcin Wawrzyniak, On Behalf Of The Swiss Ibd Cohort Study Group

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. ERK1/2 in immune signalling.Biochemical Society transactions · 2022
    Review
  2. Article
  3. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yasser MorsyDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-8234-1877
Nathalie BrillantDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Yannick FrancCenter for Primary Care and Public Health (Unisanté), University of Lausanne, 1101 Lausanne, Switzerland.
Michael ScharlDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Marcin WawrzyniakDepartment of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
On Behalf Of The Swiss Ibd Cohort Study Group
University of Zurich · CHCentre universitaire de médecine générale et santé publique, Lausanne · CH

Funding

CSRD VA 1Stiftung Experimentelle Biomedizin 2017Swiss National Science Foundation 314730-146204Swiss National Science Foundation 314730_166381Swiss National Science Foundation 320030_184753Swiss National Science Foundation 33CS30_177523
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease ProgressionGenetic LociGenetic Predisposition to DiseaseAdolescentAdultAllelesArthritisColitis, UlcerativeCrohn DiseaseCytokinesFactor Analysis, StatisticalFemaleHumansInflammatory Bowel DiseasesMaleMAP Kinase Kinase KinasesCytokinesMAP3K8 protein, humanMAP Kinase Kinase KinasesProto-Oncogene ProteinsRNA, MessengerCrohn’s diseaseIBDTPL2ulcerative colitis

Identifiers

PMID34944097
PMCPMC8700574
OpenAlexW4200191385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.